uniQure N.V. (QURE) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

uniQure N.V. (QURE) Healthcare & Pipeline Overview

uniQure N.V. is a gene therapy company specializing in the development of innovative treatments for genetic and other devastating diseases. Their pipeline includes programs targeting hemophilia B, Huntington's disease, Parkinson's disease, and Alzheimer's disease, positioning them as a key player in the rapidly evolving gene therapy market.

What Is the Investment Thesis for QURE?

uniQure presents a notable research candidate within the gene therapy space. The company's lead program, Etranacogene dezaparvovec (AMT-061), nearing potential market approval for hemophilia B, could generate substantial revenue. Positive Phase III trial results and subsequent regulatory approvals are key catalysts. The company's diversified pipeline, targeting diseases like Huntington's and Parkinson's, offers long-term growth potential. However, high R&D costs, regulatory hurdles, and competition from other gene therapy companies pose risks. With a market capitalization of $3.39B and a negative profit margin of -1154.4%, uniQure's future success hinges on successful commercialization and pipeline advancement.

Based on FMP financials and quantitative analysis

QURE Key Highlights

Market capitalization of $3.39B reflects investor confidence in uniQure's gene therapy pipeline.

• Gross margin of 57.8% indicates strong potential profitability upon commercialization of its therapies.
• Etranacogene dezaparvovec (AMT-061) in Phase III HOPE-B pivotal trial represents a near-term catalyst for potential revenue generation.
• Pipeline includes programs targeting Huntington's disease, Parkinson's disease, and Alzheimer's disease, offering long-term growth opportunities.
• Beta of 0.75 suggests lower volatility compared to the overall market.

Who Are QURE's Competitors?

QURE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are QURE's Key Strengths?

Proprietary AAV gene therapy platform.

• Advanced clinical pipeline.
• Experienced management team.
• Strong intellectual property position.

What Are QURE's Weaknesses?

High R&D costs.

• Dependence on clinical trial outcomes.
• Regulatory hurdles.
• Limited commercialization experience.

What Could Drive QURE Stock Higher?

Etranacogene dezaparvovec (AMT-061) regulatory approval decisions for hemophilia B.

• Clinical data updates from the AMT-130 program for Huntington's disease.
• Enrollment and data readouts from ongoing clinical trials.
• Potential new partnerships and collaborations.

What Are the Key Risks for QURE?

Financial-distress signal — its Altman Z-Score of 1.27 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Adverse clinical trial results.
• Regulatory delays or rejections.
• Competition from other gene therapy companies.
• High R&D expenses.
• Manufacturing challenges.

What Are the Growth Opportunities for QURE?

• Etranacogene dezaparvovec (AMT-061) Commercialization: The successful completion of the Phase III HOPE-B trial and subsequent regulatory approval for Etranacogene dezaparvovec (AMT-061) represents a significant growth opportunity. The hemophilia B market is estimated to be worth billions of dollars, and uniQure could capture a substantial share with a successful gene therapy product. Timeline: Potential market launch within the next 1-2 years, pending regulatory approvals.
• Expansion of Huntington's Disease Program (AMT-130): The AMT-130 program for Huntington's disease is currently in Phase I/II clinical trials. Positive clinical data and subsequent advancement to later-stage trials could unlock a significant market opportunity. Huntington's disease is a debilitating neurodegenerative disorder with limited treatment options. Timeline: Clinical data updates expected in the next 12-18 months.
• Advancement of Parkinson's Disease Program (AMT-210): uniQure's AMT-210 program targets Parkinson's disease, another major neurodegenerative disorder. Preclinical and early clinical data will be crucial for determining the program's potential. The Parkinson's disease market is substantial, with a growing need for effective therapies. Timeline: Early-stage clinical trials ongoing, with potential for advancement in the next 2-3 years.
• Development of Alzheimer's Disease Program (AMT-240): The AMT-240 program focuses on autosomal dominant Alzheimer's disease. While still in the preclinical stage, successful development could address a significant unmet medical need. The Alzheimer's disease market is one of the largest in the pharmaceutical industry. Timeline: Preclinical studies ongoing, with potential for clinical trials in the next 3-4 years.
• Strategic Partnerships and Collaborations: uniQure can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its gene therapy programs. These partnerships can provide access to funding, expertise, and global market reach. Timeline: Ongoing, with potential for new partnerships to be announced in the near future.

What Are QURE's Competitive Advantages?

• Proprietary AAV gene therapy platform.
• Strong intellectual property portfolio.
• Expertise in gene therapy development and manufacturing.
• First-mover advantage in certain disease areas.

What Does QURE Do?

Founded in 1998 and headquartered in Amsterdam, the Netherlands, uniQure N.V. is a pioneering gene therapy company dedicated to transforming the lives of patients suffering from genetic and other severe diseases. The company's mission is to develop and deliver innovative gene therapies that address unmet medical needs. uniQure's lead program, Etranacogene dezaparvovec (AMT-061), is currently in Phase III clinical trials (HOPE-B pivotal trial) for the treatment of hemophilia B, a genetic bleeding disorder. Beyond hemophilia B, uniQure is also developing a pipeline of gene therapy candidates targeting other debilitating conditions, including Huntington's disease (AMT-130, Phase I/II), Parkinson's disease (AMT-210), temporal lobe epilepsy (AMT-260), autosomal dominant Alzheimer's disease (AMT-240), and amyotrophic lateral sclerosis (AMT-161). uniQure leverages its proprietary AAV (adeno-associated virus) gene therapy platform to deliver therapeutic genes directly to target cells, offering the potential for long-lasting or even curative treatment outcomes. The company's focus on innovative gene therapy solutions positions it as a significant player in the biotechnology industry, with the potential to address a wide range of genetic disorders.

What Products and Services Does QURE Offer?

• Develop gene therapies for genetic diseases.
• Focus on adeno-associated virus (AAV) gene therapy platform.
• Lead program targets hemophilia B (Etranacogene dezaparvovec).
• Develop therapies for Huntington's disease, Parkinson's disease and Alzheimer's disease.
• Conduct clinical trials to evaluate the safety and efficacy of gene therapies.
• Seek regulatory approvals for gene therapy products.
• Commercialize gene therapies upon regulatory approval.

How Does QURE Make Money?

• Develop proprietary gene therapy products.
• Out-license or co-develop gene therapies with pharmaceutical partners.
• Generate revenue through product sales upon regulatory approval.
• Receive milestone payments and royalties from partnered programs.

What Industry Does QURE Operate In?

The biotechnology industry is experiencing rapid growth, driven by advancements in gene therapy and personalized medicine. uniQure operates in a competitive landscape with companies like EWTX: Edgewise Therapeutics, Inc. and others developing gene therapies for various genetic disorders. The success of uniQure depends on its ability to navigate regulatory hurdles, secure partnerships, and effectively commercialize its products.

Who Are QURE's Key Customers?

• Patients suffering from genetic diseases.
• Healthcare providers who treat patients with genetic diseases.
• Pharmaceutical companies seeking to partner on gene therapy development.
• Payers (insurance companies and government healthcare programs) who reimburse for gene therapy treatments.

Wall Street analysts project uniQure N.V. revenue of about $22.4M for fiscal 2026, with EPS near $-3.92. The estimate reflects 8 contributing analysts.

Quarterly Financial Performance: uniQure N.V.

Revenue for uniQure N.V. came in at $5.8M during Q2 2026, a 64.0% improvement versus the preceding quarter. The company recorded a net loss of $81.1M, with diluted EPS of $-1.22. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, QURE averaged $-1.01 in diluted EPS.

QURE Valuation & Market Position

With a $3.39B market cap, uniQure N.V. sits in the mid-cap segment of the market. Relative to its peer group, QURE's quantitative score of 45/100 is below the peer average of 80/100.

Key Financial Metrics

Return on assets is -26.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.40 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.8%, the inverse of the P/E and a quick read on earnings relative to price.

uniQure N.V.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.27 places it in the distress zone, a signal of elevated financial risk.

uniQure N.V. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 19.1% below estimates on average.

Company Profile

uniQure N.V. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Amsterdam, NL. The company is led by CEO Matthew Kapusta. QURE has traded publicly since 2014.

QURE Financials

QURE Latest News

QURE Analyst Consensus

QURE MoonshotScore

Latest uniQure N.V. Analysis

uniQure N.V. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources